• Profile
Close

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: An analysis from the DECLARE–TIMI 58 randomised trial

The Lancet Diabetes & Endocrinology Jul 20, 2019

Mosenzon O, et al. - In patients with type 2 diabetes, researchers analyzed the impacts of dapagliflozin on development and progression of kidney disease. For this investigation, subjects with type 2 diabetes, HbA1c 6.5–12.0% (47.5–113.1 mmol/mol), with either established atherosclerotic cardiovascular disease or multiple risk factors, and creatinine clearance of at least 60 mL/min were randomized (1:1) to 10 mg dapagliflozin or placebo once daily. In this large and diverse population of patients with type 2 diabetes with and without established atherosclerotic cardiovascular disease, most of whom had preserved renal function, dapagliflozin appeared to prevent and decrease the progression of kidney disease vs placebo.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay